1.
VistaGen Therapeutics Inc.
VistaGen Therapeutics Announces Broad Stem Cell R&D Alliance With Toronto's University Health Network and The McEwen Centre For Regenerative Medicine More. ...
2.
VistaGen and Capsant Sign Strategic Stem Cell Technology ...
File Format: PDF/Adobe Acrobat - View as HTML Jan 15, 2009 ... signed a strategic commercialization agreement under which the companies will combine their leading- edge stem cell biology and 3D cell ...
3.
VistaGen
"Through the new arrangement with UHN and the McEwen Centre, a partnership that ... Parkinson's disease, brain disorders and other neurological disorders. ...
4.
VistaGen
VistaGen Therapeutics Announces Broad Stem Cell R&D Alliance With Toronto's University Health Network and The McEwen Centre For Regenerative Medicine ...
5.
Kynurenate production by cultured human astrocytes
File Format: PDF/Adobe Acrobat - View as HTML cerebral KYNA synthesis using primary cultures of human astrocytes. .... Dose-response relationship of KYNA production by human astrocytes exposed to ...
6.
VistaGen
In preclinical studies, VistaGen’s AV-101 has greater than 90% oral bio availability, ... AV-101 regulates NMDA-receptor function in the brain controlling ...
7.
Early warning system for drug dangers sought
File Format: PDF/Adobe Acrobat - View as HTML In the case of Vioxx and some other drugs, the cardiovascular danger was not fully evident until after the drugs were approved and had been taken by ...
8.
Kynurenate production by cultured human astrocytes
File Format: PDF/Adobe Acrobat - View as HTML Establishment of human astrocyte cultures and human fibroblast cultures .... Dose-response relationship of KYNA production by human astrocytes exposed to ...
9.
VistaGen
My guest today is Ralph Snodgrass. Ralph is the founder and Chief Executive Officer of the privately held biotech company VistaGen. Ralph, it is terrific ...
10.
Newly-Issued Broad Composition of Matter Patent Protects VistaGen ...
File Format: PDF/Adobe Acrobat - View as HTML Jun 16, 2008 ... new broad composition of matter patent protection for its ES Cell-derived pluripotent precursor cells. VistaGen has ...